Pipeline - Trovagene

Providing New Treatment Options Across a
Wide Array of Cancers

Demonstrated synergy of onvansertib in combination with already
approved chemotherapies and targeted therapeutics

We are developing onvansertib as part of a combination regimen across a variety of cancers and integrating a predictive clinical biomarker strategy to identify patients who are most likely to respond to treatment. The opportunity to bring new treatment options to patients in indications where there is a high medical need we believe presents significant market opportunities.

Recent News

Oct 2, 2019

Data Presented at ESMO Provides Rationale for Clinical Trial of Onvansertib in Subset of Patients with Highly-Aggressive Triple Negative Breast Cancer (TNBC)

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including breast, prostate, colorectal and leukemia, today announced the presentation of preclinical data…

Oct 1, 2019

Trovagene Presents Overview of Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer (mCRC) at ESMO

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis) for the treatment of various cancers including prostate, colorectal and leukemia, today announced the presentation of its Phase 1b/2 trial evaluating onvansertib in combination with FOLFIRI and AvastinĀ®…

Sep 30, 2019

Positive Data from Trovagene Phase 1b/2 Study of Onvansertib Featured in Oral Presentation at European Society for Medical Oncology (ESMO) Conference

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision Cancer Medicine™ oncology therapeutics company developing drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, prostate and colorectal, today announced that results from the Company’s Phase 1b/2 study…